Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $190000.0.

  • Aytu Biopharma's Non Operating Income rose 3571.43% to $190000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$803000.0, marking a year-over-year decrease of 19208.72%. This contributed to the annual value of -$512000.0 for FY2025, which is 15885.06% down from last year.
  • Latest data reveals that Aytu Biopharma reported Non Operating Income of $190000.0 as of Q4 2025, which was up 3571.43% from $201000.0 recorded in Q3 2025.
  • Aytu Biopharma's Non Operating Income's 5-year high stood at $3.7 million during Q2 2023, with a 5-year trough of -$1.2 million in Q2 2025.
  • Its 5-year average for Non Operating Income is $280350.0, with a median of $125000.0 in 2022.
  • In the last 5 years, Aytu Biopharma's Non Operating Income skyrocketed by 52741.31% in 2022 and then crashed by 112500.0% in 2025.
  • Aytu Biopharma's Non Operating Income (Quarter) stood at -$257000.0 in 2021, then tumbled by 377.82% to -$1.2 million in 2022, then skyrocketed by 107.82% to $96000.0 in 2023, then skyrocketed by 45.83% to $140000.0 in 2024, then surged by 35.71% to $190000.0 in 2025.
  • Its last three reported values are $190000.0 in Q4 2025, $201000.0 for Q3 2025, and -$1.2 million during Q2 2025.